WDL
REGN icon

Well Done LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Well Done LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-142
Closed -$53K – 537
2018
Q4 		$53K Buy
+142
New +$52K 0.01% 259
2018
Q2 		– Sell
-55
Closed -$19K – 433
2018
Q1 		$19K Buy
+55
New +$19.1K 0.01% 347

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Well Done LLC's REGN Position: Q1 2019 in Review

Well Done LLC sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 142 shares — an estimated $53K sold.

Well Done LLC first reported a position in REGN in Q1 2018 and held it in 2 quarters. The position peaked at $53K in Q4 2018. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • Well Done LLC reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Well Done LLC sold 142 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $53K.
  • Well Done LLC first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Well Done LLC's Regeneron Pharmaceuticals position peaked at $53K in Q4 2018.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Well Done LLC's 13F filing for Q1 2019, filed 9 May 2019.